Last checked at 17 Mar 2022 10:00
Hikma Pharmaceuticals PLC(the 'Company')
Publication of 2021 Annual Report and Notice of AGM
LEI: 549300BNS685UXH4JI75
The Company will today publish on its website, www.hikma.com, the Annual Report for the year ended31 December 2021 (the '2021 Annual Report').
Hard copy versions of the following documents will be sent to those shareholders who have elected to receive paper communication:
· 2021 Annual Report
· 2022 Notice of Annual General Meeting
In compliance with Listing Rule 9.6.1 of the UK Financial Conduct Authority ('FCA'), the aforementioned documents will be submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
This announcement is not a substitute for reading the 2021 Annual Report in full.
Peter Speirs | |
Company Secretary |
17 March 2022
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com